(HealthDay News) — More complete tumor resection is associated with improved long-term outcomes in patients with IDH-mutant, grade 2 glioma, according to a study published in the Journal of Clinical Oncology.
Researchers found that a resection threshold of 75% or higher was associated with improved overall survival (OS), and a threshold of 80% or higher was associated with improved progression-free survival (PFS).
Researchers conducted this 20-year retrospective study involving 392 patients with IDH-mutant, grade 2 glioma to examine the combined effects of volumetric extent of tumor resection and molecular and clinical factors on OS and PFS. The OS results were validated in 2 external cohorts with 365 participants.
Continue Reading
The researchers identified 3 survival risk groups using a recursive partitioning analysis. The shortest median OS was seen in 2 subsets of patients with astrocytoma: those who had postoperative tumor volume (TV) greater than 4.6 mL and those who had preoperative TV greater than 43.1 mL and postoperative TV of 4.6 mL or less.
Intermediate OS was seen in patients with astrocytoma who had chemotherapy with preoperative TV of 43.1 mL or less and postoperative TV of 4.6 mL or less. Intermediate OS was also seen in patients who had oligodendroglioma with preoperative TV greater than 43.1 mL and residual TV of 4.6 mL or less or postoperative residual volume greater than 4.6 mL.
The longest OS was seen in astrocytoma patients with preoperative TV of 43.1 mL or less and postoperative TV of 4.6 mL or less who received no chemotherapy, as well as in oligodendroglioma patients with preoperative TV of 43.1 mL or less and postoperative TV of 4.6 mL or less.
Several study authors disclosed financial ties to the biopharmaceutical, medical device, and health care industries.
Abstract/Full Text (subscription or payment may be required)
